Kevin Davies checks in with Alex Philippidis & I at #JPM2024. Feature interview with Liberate Bio [Khosla Ventures]. We talk news from Illumina, Institute for Geographic Information Science / Danaher Corporation; chat AI with Jason Park [Empress/Flagship Pioneering], Nicolas Tilmans [Anagenex]. genengnews.com/multimedia/pod… Genetic Engineering & Biotechnology News

Rarely do politics by Michael is one of the most eloquent, competent and kind people I know. Enthusiastically endorse Michael Lai 赖天宸 and getting more people like him into SF politics to fix our city and let its magic shine again.

This legislation impacts AI for drug discovery software businesses too: "The US becoming probably the most hostile country to run a software business with Section 174."

I sometimes worry that AI gives non deterministic outputs, but the whole internet runs on a non deterministic language so it’s probably fine.

As someone building a biotech with a foot in SF and a foot in Boston, and also a foot in tech and a foot in biochemistry, this resonates so much. It’s why we’ve aimed to hire both and build a cross functional culture. Hard but 🚀 when it works.

We are excited to have Adrian Schreyer, an experienced leader in AI enabled drug discovery, join Anagenex as Chief Technology Officer. businesswire.com/news/home/2024…

I'm thrilled to announce Adrian Schreyer as our new CTO. Adrian is a true pioneer in AI enabled drug discovery having built teams at Exscientia from founding to IPO and shepherded molecules from discovery to the clinic. I can't wait to see what he'll build with us!

Was great to talk to Jonathan D. Grinstein, PhD at GEN about our story and other scientists producing innovative solutions in AI-enabled #drugdiscovery: genengnews.com/topics/artific…

This is the way. Hype aside: make trials 2-3x more successful, we’ll still fail a lot (this is drug discovery) but we’ll save millions more lives. The current system sucks and even if we end up the same success rate, at least we took a shot to make it better.

In San Diego for the week for #BIO2024, give me a shout if you want to talk DELs or AI driven drug discovery!

This is true in Tech. It’s not true in deep tech or biotech. A good, defensible, technical idea there is maybe starting at the 10 mile line. Not halfway, still need to execute very well, but great ideas in deeper tech are rare and valuable.

The choice today is between someone who upholds our constitution or someone who tried to break it and says he will do it again. Harris's policies may not be good for Biotech or Tech. We'll see. Tearing down our system is worse. Not a hard call, vote Harris/Walz.

This is a beautiful essay on the difficulties and promise of virtual cells. I share the dream, but am skeptical our current tools will get us there, whatever “there” is. Key thing though: a model may be far short of a “virtual cell” but still be quite useful.